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Abstract
Central	to	evolutionary	theory	is	the	idea	that	living	organisms	face	phenotypic	and/
or	genetic	 trade-	offs	when	allocating	 resources	 to	 competing	 life-	history	demands,	
such	as	growth,	survival,	and	reproduction.	These	trade-	offs	are	increasingly	consid-
ered	to	be	crucial	to	further	our	understanding	of	cancer.	First,	evidences	suggest	that	
neoplastic	 cells,	 as	 any	 living	 entities	 subject	 to	 natural	 selection,	 are	 governed	by	
trade-	offs	 such	 as	between	 survival	 and	proliferation.	 Second,	 selection	might	 also	
have	shaped	trade-	offs	at	the	organismal	level,	especially	regarding	protective	mecha-
nisms	against	cancer.	Cancer	can	also	emerge	as	a	consequence	of	additional	trade-	
offs	in	organisms	(e.g.,	eco-	immunological	trade-	offs).	Here,	we	review	the	wide	range	
of	trade-	offs	that	occur	at	different	scales	and	their	relevance	for	understanding	can-
cer	dynamics.	We	also	discuss	how	acknowledging	these	phenomena,	in	light	of	human	
evolutionary	 history,	 may	 suggest	 new	 guidelines	 for	 preventive	 and	 therapeutic	
strategies.
K E Y W O R D S
cancer,	life-history	traits,	natural	selection,	trade-off
1  | INTRODUCTION
Although	 medical	 and	 evolutionary	 sciences	 have	 traditionally	 de-
veloped	 in	 relative	 isolation	 (Williams	 &	 Nesse,	 1991),	 it	 is	 widely	
acknowledged	 that	 cancer	 is	 a	process	 that	 is	 shaped	by	Darwinian	
evolution	 (Aktipis	 &	Nesse,	 2013;	Thomas	 et	al.	 2013).	 Specifically,	
cancer	 is	 driven	 by	 both	 the	 somatic	 evolution	of	 cell	 lineages	 that	
have	escaped	controls	on	replication,	and	the	evolution	of	genes	that	
influence	cancer	risk	in	populations	(Aktipis	&	Nesse,	2013;	Thomas	
et	al.,	2013).	Therefore,	applying	evolutionary	theories	to	cancer	is	rel-
evant	for	understanding	many	aspects	of	this	pathology,	from	its	origin	
per se,	 to	 possible	ways	 to	 control	 its	 progression,	 and	how	 to	pre-
vent	therapeutic	failures	(Aktipis	&	Nesse,	2013;	Rozhok	&	DeGregori,	
2015).	 Although	 these	 ideas	 first	 originated	 in	 the	 mid-	seventies	 
(e.g.,	Cairns,	1975;	Nowell,	1976),	many	promising	opportunities	 for	
the	application	of	evolutionary	biology	to	carcinogenesis	and	oncology	
remain	unexplored	(Thomas	et	al.,	2013).
Central	 to	 evolutionary	 theory	 is	 the	 assumption	 that	 living	
organisms	 are,	 at	 some	 level,	 resource-	limited	 and	 thus	must	 face	
trade-	offs	 among	 competing	 energy	 demands	 and	 life-	history	
traits,	such	as	development,	survival,	and	reproduction	(Roff,	1993;	
Stearns,	 1992).	 Life-	history	 theory	 proposes	 that	 these	 trade-	offs	
help	 to	 determine	 the	 evolution	 of	 phenotypes	 and	 could	 explain	
the	diversity	of	life-	history	patterns	found	in	biological	populations	
(Hawkins,	2004).	This	concept	has	 led	to	the	 idea	that	mammalian	
populations	 can	 be	 placed	 along	 a	 fast–slow	 continuum	 and	 has	
been	confirmed	by	 some	empirical	 evidence	 (see	Oli,	 2004	 for	 re-
view).	Species	selected	to	mature	early	have	high	reproductive	rates	
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and	short	generation	times	and	are	considered	to	have	a	“fast”	strat-
egy,	while	species	that	have	the	opposite	suite	of	traits	are	thought	
to	represent	the	“slow”	end	of	the	continuum	(Promislow	&	Harvey,	
1990;	Read	&	Harvey,	1989).
The	main	reason	why	trade-	offs	have	played	a	prominent	role	 in	
evolutionary	 thinking	 is	 their	 direct	 link	with	 processes	 limiting	 the	
adaptive	potential	of	organisms.	Trade-	offs	lead	to	antagonistic	rela-
tionships	between	phenotypic	traits	and	are	thought	to	be	determined	
both	 genetically	 and	 environmentally	 (Box	1).	 A	 large	 diversity	 of	
trade-	offs	have	so	far	been	identified,	for	example,	the	classical	trade-	
offs	between	reproduction	and	survival,	offspring	number	and	quality,	
and	current	versus	future	reproduction	(Agrawal,	Conner,	&	Rasmann,	
2010;	Stearns,	1989),	or	in	the	context	of	host–pathogen	interactions,	
between	immune	defenses	versus	reproduction	or	between	resistance	
versus	tolerance	to	pathogens	(Råberg,	Graham,	&	Read,	2009;	Sorci,	
Boulinier,	Gauthier-	Clerc,	&	Faivre,	2008).
Similar	to	other	pathologies,	the	concept	of	trade-	offs	 is	 increas-
ingly	considered	to	be	central	in	both	fundamental	and	applied	research	
on	cancer	(e.g.,	Aktipis,	Boddy,	Gatenby,	Brown,	&	Maley,	2013;	Roche	
&	Thomas,	2016).	For	instance,	the	emergence	of	malignant	cell	lines	
may	be	both	cause	and	consequence	of	evolutionary	trade-	offs.	In	ad-
dition,	most	protective	mechanisms	shaped	by	selection	against	cancer	
are	 costly	 and	 come	with	 trade-	offs	 (Hochberg,	Thomas,	Assenat,	&	
Hibner,	2013);	thus,	cancer	can	emerge	as	a	consequence	of	trade-	offs	
with	life-	history	traits	such	as	reproduction	(Aktipis	&	Nesse,	2013).
Here,	we	review	how	taking	into	account	these	trades-	offs,	from	
the	perspective	of	the	cancerous	cells	and	from	the	perspective	of	the	
host,	can	help	us	to	understand	cancer	dynamics.	With	such	evolution-
ary	approach,	we	suggest	that	it	may	be	possible	to	identify	aspects	of	
anticancer	adaptations	that	have	been	constrained	by	trade-	offs	and	
so	may	be	effective	targets	for	medical	interventions.
2  | LIFE-HISTORY TRADE-OFFS AT THE 
MALIGNANT CELL LEVEL
Cells	become	malignant	by	acquiring	genetic	mutations	that	 lead	to	
increased	 survival	 and	 reproduction.	However,	 cancer	 cells	 are	 not	
Darwinian	demons	able	to	maximize	all	fitness	components	simulta-
neously;	 instead,	 recent	 evidence	 suggests	 that	 their	 functioning	 is	
constrained	by	a	number	of	underlying	trades-	offs	which	are	summa-
rized	in	Figure	1.
2.1 | Proliferation and survival
Because	malignancies	develop	in	environments	that	are	expected	to	
have	 limited	resources	 (e.g.,	space	and	nutrients)	 (Alfarouk,	 Ibrahim,	
Gatenby,	&	Brown,	2013),	a	first	trade-	off	in	malignant	cells	may	be	
between	cell	proliferation	and	survival.	It	has	been	predicted	that,	in	
a	“rich”	environment	with	high	cell	density,	malignant	cells	will	adopt	
a	“fast”	life-	history	with	rapid	proliferation	but	low	resistance	to	ap-
optosis,	 whereas	 in	 adverse	 environments,	 cells	 will	 have	 a	 “slow”	
life-	history,	with	low	proliferation	but	increased	survival	(Aktipis	et	al.,	
2013;	Alfarouk	et	al.,	2013).	Cancer	cells	can	 indeed	be	categorized	
as	proliferation-	promoting	or	survival-	promoting	phenotypes,	suggest-
ing	that	they	can	display	phenotypes	“adapted”	to	their	environment	
(Aktipis	et	al.,	2013).	Selection	 for	different	 life-	history	strategies	 in	
malignant	cells	could	also	fluctuate	over	time	because	tumorigenesis	
and/or	 therapies	will	 generate	 distinct	 selective	 landscapes.	Aktipis	
BOX 1 Levels of analysis
Trade-	offs	exist	at	different	levels,	namely	phenotypic,	genotypic,	and	at	intermediate	structures,	which	lie	between	the	other	two	(Stearns,	
1989).	The	phenotypic	level	concerns	whole-	organism	studies	of	traits	directly	connected	with	ontogeny,	reproduction,	and	survival.	For	
instance,	organisms	acquire	limited	resources	and	then	differentially	allocate	them	to	competing	functions	such	as	growth,	survival,	and	
reproduction.	The	genotypic	level	refers	to	all	types	of	evidence	claimed	to	be	genetic	(using	quantitative,	Mendelian,	or	molecular	genetics	
approaches).	This	evolutionary	level	reflects	the	constraints	(negative	genetic	correlations)	operating	on	multiple	traits	that	are	linked	in	
ways	that	prevent	simultaneous	optimization	of	all	of	them.	By	intermediate	structure,	we	imply	all	mechanisms	connecting	the	genotypic	
to	the	phenotypic	levels,	including	physiological	and	developmental	mechanisms	under	endocrinological	control	that	result	in	the	allocation	
of	resources	among	the	functions	of	maintenance,	growth,	storage,	reproduction,	and	survival	(Stearns,	1989).	Finally,	two	kinds	of	trade-	
offs	are	recognized,	those	for	which	opposing	selection	across	different	environments	results	in	a	polymorphic	trait	and	trade-	offs	which	
are	the	consequences	of	competition	for	shared	limiting	resources	and	that	act	on	multiple	traits	(Agrawal	et	al.,	2010).
F I G U R E  1  Tumor	dynamics	rely	on	numerous	trade-	offs	at	the	
malignant	cell	level.	Neoplastic	cells	have	to	face	numerous	 
trade-	offs	to	increase	their	fitness	in	the	host
Cooperation/egoism
Malignant cells
TUMOR DYNAMICS
Proliferation/survival
Dispersal/proliferation
Resistance/proliferation
Defense against aggressors
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et	al.	 (2013)	hypothesized	that	 these	trade-	offs	may	only	happen	 in	
later	 stages	of	 tumorigenesis,	 favoring	extreme	phenotypes	such	as	
rapidly	proliferating	cells	with	poor	survival	abilities	or	apparently	dor-
mant	cells	that	can	survive	extremely	well.
2.2 | Dispersal and cell plasticity
Many	 animals	 disperse	 to	 reduce	 intraspecific	 competition	 (Fahrig,	
2007).	Models	 in	evolutionary	ecology	have	also	shown	that	organ-
isms	should	move	only	when	the	costs	of	“staying	at	home”	outweigh	
the	 potential	 costs	 of	 leaving	 the	 natal	 habitat	 (North,	 Cornell,	 &	
Ovaskainen,	2011).	Cancer	cells	within	organs	face	the	same	trade-	
off	(Lee,	Silva,	Li,	&	Slifker,	2011;	Marusyk	&	Polyak,	2010),	and	they	
can	 switch	 between	 migratory	 and	 proliferative	 phenotypes	 (e.g.,	
squamous	cell	carcinoma;	Biddle	et	al.,	2011).	A	theoretical	study	has	
proposed	that	neoplastic	cells,	with	deregulated	metabolism,	may	be	
selected	 to	 have	 higher	motility	 because	 their	 survival	 depends	 on	
their	ability	to	move	from	a	resource-	restricted	region	to	a	new	envi-
ronment	that	can	sustain	their	high	metabolic	needs	(Aktipis,	Maley,	&	
Pepper,	2012).	Moreover,	numerous	evidences	suggested	that	when	
malignant	cells	are	exposed	to	poor	“environmental	conditions”	 (hy-
poxia,	toxins,	etc.)	or	when	resources	are	spatially	or	temporally	het-
erogeneous	(oxygen,	nutrients,	etc.),	selection	might	favor	metastatic	
cancer	phenotypes	(Anderson	et	al.,	2006;	Chen,	Sprouffske,	Huang,	
&	Maley,	2011;	Daoust	et	al.,	2013;	but	see	Arnal	et	al.,	2016).	In	addi-
tion	to	these	theoretical	studies,	it	has	been	observed	in	a	murine	lung	
cancer	model	that	toxicity	mediated	by	the	chemotherapy	may	induce	
metastasis	(Daenen	et	al.,	2011).
Cell	plasticity	is	pervasive	in	cancer	stem	cells	which	can	be	pro-
liferative	or	quiescent	according	to	factors	describing	the	tumor	mi-
croenvironment,	with	 the	 potential	 to	 influence	 cellular	metabolism	
(DeBerardinis,	Lum,	Hatzivassiliou,	&	Thompson,	2008).	Because	phe-
notypic	plasticity	in	organisms	has	been	shown	to	be	costly	(DeWitt,	
Sih,	 &	Wilson,	 1998),	 exploring	 the	 costs	 for	malignant	 cells	 of	 ex-
pressing	conditional	 life-	history	strategies	 (e.g.,	 cell	plasticity)	 in	dif-
ferent	environments	is	also	a	promising	direction	for	management	of	
tumorigenesis	(Aktipis	et	al.,	2013).
2.3 | Dispersal and cell plasticity
As	infectious	agents	do,	cancer	cells	are	able	to	develop	adaptations	
to	resist	to	therapeutic	drugs.	Most	of	them	relay	on	pumps	that	ex-
pulse	and	reduce	intracellular	concentrations	of	cytotoxic	drugs	such	
as	ATP-	binding	 cassette	 (ABC)	drug	 transporters	 commonly	 implied	
in	multidrug	resistance	(MDR)	(Fletcher,	Haber,	Henderson,	&	Norris,	
2010).	It	has	been	observed	that	even	if	MDR	lines	(i.e.,	MCF-	7/Dox)	
do	not	show	constrained	proliferation	or	survival	in	glucose-	rich	envi-
ronment,	they	show	a	significantly	decreased	proliferation	in	glucose-	
limited	conditions	because	of	their	higher	ATP	demands	(Kam	et	al.,	
2011).	Strategies	taking	advantage	of	the	trade-	off	between	prolifera-
tion	and	resistance	have	given	rise	to	adaptive	therapies.	Such	evolu-
tionary	approaches	aim	to	combine	the	immediate	cytotoxic	effects	of	
treatments	with	the	ultimate	goal	of	exploiting	the	adaptive	responses	
of	 tumor	 cells	 (Gatenby,	 Brown	 et	al.,	 2009;	 Gatenby,	 Silva	 et	al.,	
2009).	For	example,	a	theoretical	approach	has	confirmed	that	selec-
tion	of	 chemosensitive	 cells	 has	 the	 potential	 to	 destroy	malignant	
cells	through	competition	(Maley	et	al.,	2004).	Sensitive	cells	may	be	
selected	using	a	combination	of	cytotoxic	drugs	with	drugs	decreasing	
energy	production	which	may	accentuate	the	cost	of	resistance	and	
suppress	the	proliferation	of	drug-	resistant	clones	(Silva	et	al.,	2012).	
Indeed,	a	new	treatment	strategy,	designed	in	murine	breast	cancer	
model,	has	allowed	a	continuous	decline	in	tumor	size	even	with	long	
intervals	between	treatments	through	exploitation	of	the	fitness	cost	
of	resistance	(Enriquez-	Navas	et	al.,	2016).
2.4 | Defenses against multiple aggressors
Decades	of	research	in	applied	ecology	have	illustrated	that	the	evo-
lution	of	defenses	 against	one	natural	 enemy	affects	 the	 individual’s	
ability	 to	 defend	 against	 other	 enemies,	 and/or	 to	 optimally	 express	
other	fitness-	related	traits	(Moret	&	Schmid-	Hempel,	2000;	Sheldon	&	
Verhulst,	1996).	The	presence	of	multiple	enemies	can	modify	the	re-
sistance	against	one	specific	enemy,	with	the	direction	of	evolutionary	
change	depending	on	enemy	encounter	rates,	defense	costs,	and	mech-
anistic	 interactions	 among	 defense	 mechanisms	 (Poitrineau,	 Brown,	
&	Hochberg,	2003).	Cancer	 cells,	 like	organisms,	have	 to	 face	attack	
from	many	different	biotic	and	abiotic	aggressors,	for	example,	immune	
system,	oncolytic	viruses,	and	therapies.	It	is	now	well	recognized	that	
cancer	cells	can	evolve	resistance	mechanisms	to	both	chemotherapy	
(Gottesman,	 2002)	 and	 immunotherapy	 (Restifo,	 Smyth,	 &	 Snyder,	
2016).	As	 investment	 in	one	defense	could	 influence	 the	 level	of	 in-
vestment	in	another,	it	has	been	suggested	that	biological	and	chemical	
therapies	could	be	coupled	in	a	strategic	multistep	approach	(De	Pillis	
et	al.,	2006).	In	agreement	with	this	view,	evidence	shows	that	tumor	
cells	able	to	successfully	adapt	to	an	immune	attack	are	more	sensitive	
to	the	cytotoxic	effects	of	chemotherapy	(Antonia	et	al.,	2006).
3  | LIFE- HISTORY TRADE- OFFS 
AT THE ORGANISM LEVEL
3.1 | Host protective mechanisms
Regarding	 fitness-	reducing	 diseases,	 evolutionary	 theory	 postulates	
that	 organisms	 should	 be	 under	 selective	 pressure	 to	 (i)	 avoid	 the	
source	of	the	pathology	in	the	first	instance,	(ii)	then	prevent	its	pro-
gression	once	sick,	and	(iii)	finally	alleviate	the	fitness	costs	if	further	
development	is	unavoidable	(Thomas,	Guégan,	&	Renaud,	2009).	This	
conceptual	framework	applies	also	to	cancer	and	relies	on	trade-	offs	
(Ujvari	et	al.,	2016).
3.1.1 | Cancer prevention
Environmental	 factors	 favoring	 cancer	 emergence	 and/or	 progres-
sion	are	potentially	numerous,	their	origins	being	both	anthropogenic	
(e.g.,	radioactivity;	Møller	&	Mousseau,	2015)	and	natural	(e.g.,	natural	
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radiation	levels,	oncogenic	pathogens,	transmissible	cancers,	and	sec-
ondary	compounds	of	plants)	 (Ducasse	et	al.,	2015).	 In	 this	context,	
it	is	predicted	that	traits	allowing	individuals	to	reduce	the	frequency	
or	the	duration	of	exposure	to	those	factors	could	be	favored	by	se-
lection	as	 they	decrease	 cancer	 risk,	 but	will	 likely	 also	entail	 costs	
(Vittecoq	et	al.,	 2015).	Being	 choosy	 to	 avoid	 cancer	 risks	 (with	 re-
spect	to	habitat,	food,	or	partners	with	a	contagious	cancer)	may	entail	
a	cost	 that	 is	higher	when	competition	 is	more	 intense.	 In	addition,	
adopting	a	lifestyle	reducing	exposure	to	mutagenic	factors	may	result	
in	a	small	selective	advantage	if	most	cancers	are	due	to	intrinsic	fac-
tors	(Thomas,	Roche	et	al.	2016;	Tomasetti	&	Vogelstein,	2014).	Thus,	
considering	 that	 the	probability	 of	 developing	 an	 aggressive	 cancer	
before	or	during	 the	 reproductive	period	 is	 low	 (Ujvari	 et	al.,	2016)	
and	that	the	perception	of	cancer	risk	may	be	unreliable,	the	benefit	
of	prevention	may	be	offset	by	its	cost.
Even	when	 a	 given	 trait	 (e.g.,	 behavior)	 strongly	 contributes	 to	
protect	 an	 individual	 from	 a	 fitness-	impacting	 cancer,	 it	 may	 not	
necessarily	 increase	 in	 frequency	 in	 the	population.	 Indeed,	when	a	
trait	is	both	essential	to	the	host’s	survival	and	reproduction,	but	also	
enhances	cancer	risks,	it	will	be	subject	to	an	evolutionary	trade-	off.	
Natural	selection	will	most	likely	favor	individuals	whose	trait	expres-
sion	ensures	the	optimal	compromise	between	satisfying	a	need	(e.g.,	
reproduction)	and	minimizing	the	risk	of	detrimental	consequences	on	
health	 (Vittecoq	et	al.,	2015).	For	 instance,	 in	the	case	of	Tasmanian	
devil (Sarcophilus harrisii)	 and	 their	 contagious	 cancer	 (Murchison,	
2009;	Pye	et	al.,	2016),	natural	selection	cannot	strongly	favor	individ-
uals	avoiding	conspecifics,	because	at	the	same	time,	sexual	selection	
favors	individuals	displaying	aggressive	biting	behavior	that	increases	
mating	and	breeding	success	(Ujvari	et	al.,	2016).
Thus,	despite	the	abundance	of	ecological	contexts	that	are	asso-
ciated	with	cancer	risks,	there	are	only	a	few	demonstrated	examples	
of	behavioral	adjustments	in	wildlife	species	related	to	cancer	preven-
tion	(e.g.,	antioxidant	consumption;	Senar	et	al.,	2010).	Acknowledging	
that	most,	 if	 not	 all,	 ecosystems	on	our	planet	 are	now	polluted	by	
mutagenic	substances	to	a	greater	extent	than	ever	before	(Ducasse	
et	al.,	2015),	it	is	predicted	that	natural	selection	will	favor	cancer	pre-
vention	to	avoid	fitness	loss.	Thus,	for	numerous	species,	the	benefits	
of	behavioral	adjustments	will	surpass	their	costs	and	examples	of	pre-
vention	could	substantially	increase	in	the	future.
3.1.2 | Cancer suppression
Cancer	appeared	at	the	dawn	of	multicellularity	(i.e.,	more	than	half	
a	 billion	 years	 ago	 (Merlo,	 Pepper,	 Reid,	 &	 Maley,	 2006;	 Nunney,	
2013)),	and	a	major	aspect	of	this	transition	from	unicellular	ancestors	
has	been	the	suppression	of	cell-	level	fitness	to	promote	organism-	
level	 fitness	 (Maynard-	Smith	 &	 Szathmary,	 1997;	 Michod,	 2000).	
Effective	 multicellularity,	 therefore,	 required	 both	 cell	 cooperation	
and	 mechanisms	 for	 eliminating	 conflicts	 arising	 from	 mutations	
that	 can	enhance	 cell-	level	 fitness	 at	 the	 expense	of	 the	 individual	
organism	(Aktipis	et	al.,	2015;	Michod	&	Roze,	2001).	This	situation	
resulted	 in	 selective	pressures	 favoring	 the	evolution	of	many	can-
cer	suppression	mechanisms,	from	cell-	intrinsic	checks	that	prevent	
cellular	proliferation	and	invasion	of	other	tissues	and	organs,	to	in-
tegral	controls	that	suppress	cancer	by	operating	at	the	level	of	tis-
sue	organization.	These	mechanisms	include,	but	are	not	 limited	to,	
apoptosis,	effective	DNA	repair,	epigenetic	modifications,	cell	cycle	
checkpoints,	 telomere	 shortening,	 tissue	 architecture,	 and	 immune	
surveillance	(DeGregori,	2011).
As	 evolution	 shaped	 larger	 and	 longer	 lived	 multicellular	 organ-
isms,	the	problem	of	cancer	suppression	became	even	more	challeng-
ing	(Nunney,	2013;	Peto,	Roe,	Lee,	Levy,	&	Clack,	1975).	To	counteract	
the	increased	risk	of	developing	a	cancer,	large	and	long-	lived	species	
may	have	optimized	their	tumor	suppression	mechanisms	and	adopted	
lower	somatic	mutation	rates,	redundancy	of	tumor	suppressor	genes,	
etc.	(Abegglen	et	al.,	2015;	Caulin	&	Maley,	2011).	However,	solutions	
for	suppressing	cancer	are	not	perfect,	even	if	they	are	remarkably	effec-
tive.	For	example,	tumor	suppressor	genes	and	their	resulting	products	
sometimes	 fail	 to	 repair	 double-	stranded	DNA	breaks	without	 intro-
ducing	errors	(Khanna	&	Jackson,	2001).	Multicellular	organisms	could	
theoretically	have	better	mechanisms	to	suppress	cancer,	but	the	costs	
of	such	mechanisms	might	exceed	the	benefits	when	individuals	reach	
a	postreproductive	age	(Hochberg	et	al.,	2013).	Thus,	natural	selection	
has	mainly	favored	the	evolution	of	anticancer	adaptations	that	act	be-
fore	or	during	reproductive	age	(Crespi	and	Summers2005;	DeGregori,	
2011).	Another	way	to	manage	the	cost	of	cancer	suppression	mech-
anisms	 could	be	 to	 select	 protective	 “low-	cost”	mechanisms	 that	 do	
not	 involve	complete	 tumor	elimination.	For	 instance,	auto-	immunity	
is	costly	for	organisms	and	immune	tolerance	occurs	in	response	both	
to	 infections	 (Read,	Graham,	&	Råberg,	2008)	and	cancer	 (Mapara	&	
Sykes,	2004).	Even	if	it	precludes	the	development	of	an	adequate	anti-
tumor	response,	tolerance	might	be	a	better	strategy	than	a	costly	over-
activation	of	the	immune	system.	Interestingly,	strategies	for	breaking	
this	tolerance	have	been	studied	as	therapeutic	approaches	and	led	to	
promising	results	(Makkouk	&	Weiner,	2015).	For	instance,	the	use	of	
immune	checkpoint	blockades,	that	abrogate	negative	signals	diminish-
ing	T-	cell	activation	during	the	priming	process,	has	been	approved	for	
the	treatment	of	advanced	melanoma	(Ipilimumab)	(Page	et	al.,	2012).
A	 recent	 study	 argues	 that	 adopting	 a	 more	 organ-	centered	 ap-
proach	is	desirable	for	a	full	understanding	of	organ-	specific	trade-	offs	
associated	with	cancer	suppression	mechanisms	(Thomas,	Roche	et	al.,	
2016).	Organs	are	the	products	of	adaptation	to	natural	and	sexual	se-
lection	 (Nesse	&	Williams,	1996).	The	 importance	and/role	of	various	
organs	in	keeping	the	organism	functional	and	ultimately	to	maximize	
fitness	vary	substantially.	For	 instance,	organs	such	as	heart,	brain,	or	
pancreas	are	absolutely	essential	for	survival,	while	others	such	as	gall-
bladder	are	disposable.	Organ-	specific	trade-	offs	have	already	been	sug-
gested	 in	association	with	the	energy	allocated	to	their	development.	
As	some	organs	are	considered	to	be	metabolically	expensive	such	as	
brain,	gut,	and	sexual	organs,	the	expensive-	tissue	hypothesis	suggests	
that	the	allocation	of	energy	to	develop	large	brains	results	in	a	relatively	
smaller	gut	(Aiello,	Wheeler,	&	Wheeler,	1995).	Other	studies	have	pro-
posed	an	expensive	sexual	tissue	hypothesis	that	relies	on	negative	rela-
tionship	between	investment	in	testes	and	investment	in	brain	(Pitnick,	
Jones,	&	Wilkinson,	2006).	In	the	context	of	cancer	suppression,	organ	
protection	may	not	be	maximal	but	rather	suboptimal	and	unequal	due	
     |  219JACQUELINE Et AL.
to	trade-	offs	with	the	other	organs	and	mechanisms,	preventing	malig-
nant	transformation	per se,	should	be	more	prominent	in	vital	organs	in	
order	to	preserve	their	functionality	(Thomas,	Nesse	et	al.,	2016).
Finally,	suppression	of	neoplastic	growths	may	lead	to	trade-	offs	
in	 other	 essential	 functions	 that	 require	 cell	 proliferation	 (Aktipis	&	
Nesse,	 2013).	 First,	 the	 capacity	 to	 repair	tissues	while	 limiting	un-
controlled	cell	division	represents	a	key	trade-	off	for	any	multicellu-
lar	 organism	 (Aktipis	&	Nesse,	 2013).	 Second,	 cell	 capacities	during	
embryogenesis	 and	 development	 (e.g.,	 “invasion”	 of	 cells	 into	 other	
developing	tissues	during	gastrulation),	which	are	essential	for	repro-
ducing	organisms,	 confer	 a	 risk	 for	developing	 cancer	 (Ben-	David	&	
Benvenisty,	2011).	Finally,	the	p53	protein,	with	a	well-	known	cancer-	
suppressive	function,	leads	to	reduced	tissue	renewal	and	repair,	stem	
cell	deletion,	and	organismal	aging	through	an	antagonistic	pleiotropy	
effect	 (Campisi,	 2002,	 2003;	 García-	Cao	 et	al.,	 2002).	 For	 instance,	
mice	carrying	a	p53	mutation	(with	a	phenotypic	effect	analogous	to	
the	upregulation	of	the	gene)	have	a	lower	risk	of	cancer	development,	
but	 their	 life	span	 is	 reduced	and	accompanied	by	early	tissue	atro-
phy	(Donehower,	2002;	Tyner	et	al.,	2002).	However,	a	recent	study	
contradicts	 this	 observation	 in	mice	 and	 has	 demonstrated	 that	 el-
ephants,	 that	 are	 long-	lived	mammals,	 have	 a	 high	number	of	 extra	
p53	copies	(Abegglen	et	al.,	2015).	Thus,	studying	how	elephants	have	
overstepped	the	trade-	off	that	governs	cancer	suppression	by	p53	is	
of	crucial	interest	to	design	therapies	that	reduce	the	cost	of	natural	
mechanisms	and	thus	indirectly	improve	cancer	suppression.
3.1.3 | Alleviating the fitness consequences of cancer
There	are	several	examples	in	the	parasitological	literature	illustrating	
that	hosts,	unable	 to	 resist	 infection	by	other	means	 (e.g.,	 immuno-
logical	 resistance,	 inducible	 defenses,	 or	 long-	distance	 migration),	
present	 adaptive	 and	 flexible	 life-	history	 traits	 that	 partly	 compen-
sate	parasite-	induced	fitness	 reduction	 (e.g.,	 by	 reproducing	earlier;	
Forbes,	1993;	Hochberg,	Michalakis,	&	de	Meeus,	1992;	Michalakis	
&	Hochberg,	1994).	Although	further	evidences	would	be	welcome,	
similar	life-	history	trait	adjustments	may	also	exist	in	hosts	harboring	
tumors	 (Ujvari	 et	al.,	 2016).	 From	an	 epidemiological	 point	 of	 view,	
such	responses	could	contribute	to	influence	cancer	risks	through	the	
evolution	of	differential	 cancer	 vulnerabilities.	For	 instance,	BRCA1	
and	BRCA2	mutations	are	inherited	and	predispose	women	to	breast	
and	ovarian	cancer,	but	even	though	carriers	of	these	mutations	have	
reduced	 survival,	 they	also	have	enhanced	 fertility	 (Easton,	Ford,	&	
Bishop,	1995;	Smith,	Hanson,	Mineau,	&	Buys,	2012).	Similarly,	 the	
shorter	 CAG	 repeat	 region	 within	 the	 androgen	 receptor	 gene	 in-
creases	an	individual’s	risk	of	developing	prostate	cancer,	but	it	also	
increases	fertility	earlier	in	life	(Summers	&	Crespi,	2008).	These	find-
ings	may	indicate	an	adaptive	response	to	compensate	the	risk	of	fit-
ness	loss	due	to	cancer	predisposition.	Such	adaptive	response	is	of	
considerable	significance	as	it	may	allow	the	persistence	of	mutations	
with	 deleterious	 effects	 across	 generations	 (Vittecoq	 et	al.,	 2015).	
Thus,	we	suggest	that	the	existence	of	 life-	history	trait	adjustments	
could	 influence	the	persistence	of	oncogenic	mutations	over	evolu-
tionary	time	(Ujvari	et	al.,	2016).
3.2 | Costs of reproduction
Evolution	produces	biological	entities	that	tend	to	increase	reproduc-
tive	success,	sometimes	at	the	cost	of	health	and	longevity.	In	fact,	the	
presence	of	 early-	/late-	life	 trade-	offs	 has	 been	 supported	 and	 sug-
gests	that	individuals	have	to	trade	somatic	maintenance	later	in	life	
for	high	allocation	to	reproduction	early	in	life	because	of	resource-	
limited	 environments	 (Lemaitre	 et	al.,	 2015).	 Costs	 of	 reproduction	
are	therefore	fundamental	to	understand	diseases,	 including	cancer.	
Mechanisms	underlying	the	cost	of	reproduction	are	numerous	from	
hormonal	 regulation	 to	 reduced	 immune	 functioning	 and	 lower	 de-
fenses	against	stress	and	toxicity	(Harshman	&	Zera,	2007).	This	sug-
gests	 that	 selection	 for	 increased	 reproduction	 could	 also	 result	 in	
increased	cancer	susceptibility.
3.2.1 | Sexual competition
There	 is	 little	 evidence	 on	 the	 effect	 of	 intrasexual	 selection	 (e.g.,	
male–male	agonistic	interactions)	on	cancer	risk.	In	the	case	of	a	very	
specific	type	of	cancer,	the	transmissible	Tasmanian	devil	tumor	dis-
ease,	 it	has	been	reported	that	Tasmanian	devils	have	higher	risk	of	
contracting	 cancer	when	 they	 compete	with	other	males	 for	mates	
(Hamede,	Bashford,	McCallum,	&	Jones,	2009;	Pearse	&	Swift,	2006).
In	the	context	of	intersexual	selection,	secondary	sexual	traits	(e.g.,	
impressive	 ornaments)	 may	 also	 select	 for	 mechanisms	 that	 enable	
rapid	cell	proliferation	 that	could,	 in	 turn,	enhance	 tumor	 formation	
as	suggested	by	a	theoretical	study	(Boddy	et	al.,	2015).	 In	addition,	
enhanced	allocation	of	energy	to	secondary	sexual	traits	rather	than	
to	mechanisms	of	somatic	maintenance	 (DNA	repair	or	 immune	de-
fenses)	 could	also	elevate	cancer	 risk	by	 increasing	accumulation	of	
somatic	mutations	(Boddy	et	al.,	2015).	Knowing	that	success	in	mat-
ing	competition	has	greater	 reproductive	payoffs	 for	males	 than	 for	
females,	investment	in	competitive	abilities	at	the	expense	of	cancer	
risks	 should	be	particularly	prominent	 in	males.	Antagonistic	pleiot-
ropy	might	also	favor	the	persistence	of	mutations	that	confer	a	repro-
ductive	benefit	to	the	carrier	even	if	they	increase	the	cancer	risk	of	an	
individual.	For	example,	in	Xiphophorus	fish,	melanoma-	promoting	on-
cogene	alleles	are	associated	with	larger	body	size	and	aggressiveness	
and	confer	early-	life	advantages	in	male–male	competition	and	female	
mate	choice	(Fernandez	&	Bowser,	2010;	Fernandez	&	Morris,	2008).	
One	important	limitation	to	studying	the	link	between	sexual	compe-
tition	and	cancer	risk	is	methodological	constraints.	Generally,	inves-
tigations	of	organisms	in	the	wild	do	not	test	living	individuals	for	the	
presence	of	tumors	and	the	assessment	of	the	cause	of	death	is	often	
impossible.	Development	of	noninvasive	methods	to	detect	cancer	as	
well	as	population	monitoring	is	crucial	to	progress	our	understanding	
of	the	impact	of	trade-	offs	between	reproduction	and	cancer	risk.
3.2.2 | Sexual hormones
Estrogens	 are	 the	 principal	 hormones	 that	 regulate	 the	 female	 re-
productive	 cycle	 and	 have	 been	 particularly	 associated	with	 recep-
tive	behaviors	(Lynch,	Rand,	Ryan,	&	Wilczynski,	2005).	Thus,	females	
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producing	high	levels	of	estrogens	could	be	selected	in	a	context	of	
intrasexual	 competition.	Recent	 studies	have	highlighted	 the	 strong	
interactions	between	estrogens	 and	 immune	 system	activation	 (see	
Khan	&	Ansar	Ahmed,	2016	for	review).	High	levels	of	estrogens	during	
pregnancies	could	increase	cancer	cell	elimination	and	could	explain	
the	negative	correlation	between	parity	and	risk	for	several	cancers	
(Chen,	Gong,	&	Wu,	2016;	Wu	et	al.,	2015).	Nevertheless,	evidence	
suggests	 that	 circulating	 estrogens	 are	 associated	 with	 increased	
postmenopausal	 breast	 cancer	 risk	 (Key,	Appleby,	 Barnes,	 Reeaves,	
&	 Al,	 2002),	 suggesting	 antagonist	 pleiotropy	 even	 if	 mechanisms	
are	not	well	 identified.	Finally,	modification	of	modern	reproductive	
patterns	 has	 been	 associated	with	 an	 increase	 in	 estrogen-	positive	
receptor	(ER+)	breast	cancer	suggesting	that	women	experience	the	
cost	of	a	modernity	mismatch	(Aktipis,	Ellis,	Nishimura,	&	Hiatt,	2014).
For	males,	 testosterone	has	 been	 reported	 to	 have	 an	 immuno-
modulatory	role	by	reducing	cytokine	responses	to	infection	(Trumble	
et	al.,	2016).	Regarding	cancer	development,	Alvarado	(2013)	provided	
evidence	that	in	human	subpopulations	where	competition	is	intense	
(e.g.,	polygamous	societies),	males	have	higher	testosterone	levels	and	
increased	mating	success,	but	at	the	cost	of	increased	rates	of	prostate	
cancer.	However,	recent	studies	do	not	report	significant	association	
between	 testosterone	concentrations	and	prostate	cancer	 (Roddam,	
Allen,	Appleby,	&	Key,	2008).	Nevertheless,	considering	hormones	in-
volved	in	reproductive	behaviors	could	be	of	interest	in	social	species	
with	hierarchical	dominance.	 In	 fact,	 subordinate	 individuals	 show	a	
high	level	of	stress	associated	with	low	levels	of	circulating	testoster-
one,	but	also	with	a	suppressed	immune	system	through	production	
of	 glucocorticoids	 (Sapolsky,	 2016).	 Social	 species,	 with	 differential	
cancer	risk	between	dominant	and	subordinate	 individuals,	could	be	
a	relevant	biological	model	to	study	interactions	between	sexual	hor-
mones,	immune	system,	and	cancer	development.
3.3 | Eco- immunological trade- offs
3.3.1 | Infectious disease burdens
Throughout	 evolutionary	 history,	 humans	 have	 been	 exposed	 to	
a	 large	 number	 of	 diverse	 infectious	 agents	 (Wolfe,	 Dunavan,	 &	
Diamond,	 2007).	 In	 wealthy	 countries,	 the	 decreased	 prevalence	
of	 infectious	 diseases,	 in	 particular	 of	 those	 caused	 by	 helminths,	
has	been	paralleled	by	 an	 increased	 incidence	of	 cancers	 (Zacharia,	
Zacharia,	&	Sherman,	2003).	The	helper	T	 lymphocytes	may	have	a	
central	role	for	understanding	the	link	between	infections	and	cancer	
dynamics.	 In	 fact,	 several	 studies	 have	 shown	 that	Th1	 response	 is	
protective	against	several	cancers	(Haabeth	et	al.,	2011;	Ingels	et	al.,	
2014)	and	intracellular	pathogens.	In	contrast,	Th2	activation	is	linked	
to	negative	prognosis	 in	some	cancers	(Lippitz,	2013)	and	it	confers	
protection	 against	 macroparasites.	 A	 trade-	off	 may	 exist	 because	
the	cytokines	that	instruct	immune	cells	to	differentiate	into	the	Th1	
pathway	tend	to	inhibit	Th2	effectors	(Kidd,	2003).	As	selection	may	
have	favored	one	specific	pathway	at	the	expense	of	the	other	in	our	
ancestral	environment,	the	rapid	and	radical	change	of	our	infectious	
environment	may	 create	 a	mismatch	with	 consequences	 for	 cancer	
risk	 (Oikonomopoulou	et	al.,	 2013).	One	example	of	 such	 a	 genetic	
trade-	off	comes	from	the	relative	vulnerability	of	African	Americans	
to	malignant	diseases	compared	with	Caucasian	Americans	 (Walker,	
Figgs,	&	Zahm,	1995).	Relocation	of	Africans	from	tropical	countries,	
where	inflammation	following	Th2	activation	was	beneficial,	to	North	
America,	and	the	consequent	decrease	in	infection	risk,	may	have	ex-
posed	them	to	a	higher	risk	of	cancer	(O’Byrne	&	Dalgleish,	2000).	The	
use	of	 immunoregulatory	helminth	products	has	been	 suggested	 to	
reduce	inappropriate	pro-	inflammatory	responses	and	thereby	cancer	
risk	(Finlay,	Walsh,	&	Mills,	2014).
3.3.2 | Sleep
Another	trade-	off	may	exist	between	developing	a	powerful	immuno-
logical	memory	to	eradicate	cancer	by	sleeping	longer	and	short-	term	
survival	by	prospecting	 for	 food	and	 limiting	predation	 risk.	 In	 fact,	
by	avoiding	 long	periods	of	sleep,	species	reduce	their	risk	of	being	
predated	(Lima,	Rattenborg,	Lesku,	&	Amlaner,	2005).	Humans	are	not	
an	exception,	and	 it	has	been	proposed	that	human	sleep	has	been	
selected	to	be	deeper	but	significantly	shorter	than	for	other	primate	
species	 (Samson	&	Nunn,	 2015).	However,	 it	 has	 been	 shown	 that	
sleep	has	a	specific	 role	 in	 the	 formation	of	 immunological	memory	
(Besedovsky,	Lange,	&	Born,	2012).	A	 link	between	cancer	 risk	and	
sleep	has	been	 identified	 in	a	cohort	of	women	with	breast	cancer,	
where	 it	 has	 been	 reported	 that	 women	 who	 routinely	 sleep	 few	
hours	may	 develop	more	 aggressive	 breast	 cancers	 compared	with	
women	who	sleep	long	hours	(Thompson	&	Li,	2013).
3.3.3 | Growth
At	the	species	level,	immunity	could	trade-	off	against	growth.	Species	
with	a	long	embryonic	period	have	been	hypothesized	to	invest	more	
energy	to	develop	an	immune	system	that	is	able	to	resist	to	infections	
(Ricklefs,	1992).	Thus,	because	species	with	higher	growth	rates	will	
be	 those	with	higher	 rates	of	cell	division	and	weaker	 immune	sys-
tems,	they	should	also	be	those	with	higher	incidence	of	tumors	(van	
der	Most,	de	Jong,	Parmentier,	&	Verhulst,	2011).
4  | CONCLUDING 
REMARKS AND PERSPECTIVES
There	are	some	compelling	indications	that	cancer	dynamics	may	rely	
on	and	perhaps	originate	from	numerous	trade-	offs	at	the	malignant	
cell	and	the	organismal	level	(i.e.,	ontogenetic,	physiological,	and	ana-
tomical	scales	summarized	in	Figure	2).	Acknowledging	it	not	only	per-
mits	us	to	highlight	fundamental	processes	governing	cancer,	but	also	
allows	us	identifying	tools	that	could	be	useful	in	the	development	of	
new	therapeutics.
At	the	cellular	 level,	future	studies	taking	an	evolutionary–eco-
logical	perspective	into	account	are	needed	to	uncover	novel	adap-
tations	of	malignant	cells	and	elucidate	the	trade-	offs	under	which	
they	 have	 evolved.	 Such	 knowledge	 could	 lead	 to	 therapies	 that	
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favor	cancer	cells	with	slow	life-	history	strategies	(high	survival,	low	
dispersal,	 and	 slow	 development),	 thereby	 allowing	 for	 long-	term	
cancer	 control	 (Aktipis	 et	al.,	 2013).	 Emerging	 disciplines	 such	 as	
evolutionary	 cell	 biology	 (Lynch	et	al.,	 2014)	 are	promising	 for	un-
derstanding	the	diversity	of	trade-	offs	governing	the	functioning	of	
malignant	 cells,	 their	 consequences	 for	 tumor	 evolution,	 and	 their	
implications	for	novel	therapies.	For	example,	certain	malignant	cells	
may	 behave	 as	 social	 parasitic	 clones	within	 the	 tumor	 benefiting	
from	the	metabolic	investment	made	by	their	neighbors	(e.g.,	stim-
ulating	neo-	angiogenesis	and	the	release	of	growth	factors)	without	
experiencing	costs	 themselves	 (Merlo	et	al.,	2006).	 Interestingly,	 it	
has	been	proposed	that	these	“cheaters”	may	create	a	hypertumor,	
which	could	in	return	damage	or	destroy	the	original	neoplasm	(Nagy	
et	al.,	2007).	However,	 the	existence	of	 trade-	offs	at	 the	cell	 level	
(and	hence	their	potential	use	for	therapies)	implicitly	suggests	that	
resources	are	limited.	At	the	moment,	the	extent	to	which	this	is	the	
case	must	 be	 clarified	because,	 for	 instance,	malignant	 cells	 could	
manipulate	 their	 host	 to	 obtain	 higher	 level	 of	 resources	 (Tissot	
et	al.,	2016).
F I G U R E  2  Cancer	susceptibility	rely	on	numerous	trade-	offs	at	
the	individual	level.	Most	of	the	protective	mechanisms	of	the	host	
are	retained	by	selection	against	cancer	and	rely	on	underlying	trade-	
offs.	Host	susceptibility	to	cancer	can	also	emerge	as	a	consequence	
of	other	trade-	offs	in	organisms
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T A B L E  1  Different	scales	of	trade-	offs	and	their	potential	applications	in	public	health:	evidences	from	theoretical,	experimental	and	clinical	
studies
Level Trade- offs
Potential interventions suggested by 
trade- off framework
Theoretical 
references
Experimental 
references Clinical references
Cellular Proliferation/
Survival
Resource	limitation	and	normalizing	
therapy	to	favor	survival
Aktipis	et	al.,	
(2013)
Gatenby,	Silva	et	al.,	
(2009)
Dispersal/
Proliferation
Blockage	of	epithelial–mesenchymal	
transition	(EMT)
Anderson	et	al.,	
(2006);	Daoust	
et	al.,	(2013)
Aref	et	al.,	(2013),	
Davis,	Stewart,	
Thompson,	&	
Monteith,	(2014)
Resistance/
Proliferation
Adaptive	therapy Maley	et	al.,	
(2004)
Enriquez-Navas	et	al.,	
(2016)
Defenses	against	
multiple	
aggressors
Combination	of	biological	and	
chemical	therapies
De	Pillis	et	al.,	
(2006)
Machiels	et	al.,	(2001);	
Wheeler,	Das,	Liu,	Yu,	
&	Black,	(2004)
Huncharek,	Caubet,	&	
McGarry,	2001
Cooperation/
Egoism
Use	hyper-	tumor	to	destroy	original	
neoplasm
Marusyk	et	al.,	
(2014);	Nagy	
et	al.,	(2007)
Archetti,	Ferraro,	&	
Christofori,	(2015)
Individual Reproduction/
Cancer
Condom	use,	vaccines	against	
oncogenic	pathogens
Söderlund-	Strand,	
Uhnoo,	&	Dillner,	(2014)
Preventive	removal	of	the	organ	(e.g.,	
Mastectomies	for	women	BRCA1/2)
Meijers-	Heijboer	et	al.,	
(2001)
Hormonal	treatments	(e.g.,	post-	
menopausal	women	and	breast	
cancer)
Boddy	et	al.,	
(2015)
Goss	et	al.,	(2011)
Immune	tolerance/
Auto-	immunity
Immunotherapy	(e.g.,	immune	
checkpoint	inhibitors)
Beatty	et	al.,	(2011) Page	et	al.,	(2012)
Responses	to	
infection/Cancer
Use	of	helminths	regulatory	products Harnett	&	Harnett,	
(2010)
León-	Cabrera	et	al.,	
(2014)
Anti-	inflammatory	drugs Oikonomopoulou	
et	al.,	(2013)
Valle	et	al.,	(2013) Rothwell	et	al.,	(2012)
Sleep/Predation [Speculative]	Favor	longer	sleep	
(sleeping	pills)
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By	 harnessing	 modern	 technology	 as	 a	 supplement	 to	 natural	
anticancer	 adaptations	 acquired	 through	 natural	 selection,	 medi-
cal	 intervention	could	modify	trade-	offs	providing	opportunities	for	
prevention,	detection,	and	treatment	that	have	not	previously	been	
available	to	humans	(Table	1).	For	example,	we	already	employ	agents	
like	nonsteroidal	anti-	inflammatory	drugs	to	prevent	malignant	cancer	
cell	growth	(Rothwell	et	al.,	2012),	acting	through	the	reduction	of	an	
inflammatory	response	that	is	nonoptimal	in	a	modern	environment.	
In	addition,	identification	of	trade-	offs	involving	behavioral	habits	can	
lead	to	prevention,	such	as	condom	use	(to	prevent	transmission	of	
cancer-causing	viruses)	 and	 increased	 sleeping	 time,	which	 can	 re-
duce	 cancer	 risk.	 In	 a	 cancer	elimination	context,	 engaging	 the	 im-
mune	system	into	the	systematic	elimination	of	precancerous	lesions	
via	prophylactic	cancer	vaccination	is	a	promising	research	direction	
(e.g.,	Yaddanapudi	et	al.,	2012).	However,	this	intervention	technique	
becomes	 detrimental	 to	 individual	 health	 if	 it	 results	 in	 overly	 fre-
quent	(if	not	constant)	activation	of	the	immune	system.	Intervening	
with	the	body’s	own	tumor	suppressor	mechanisms	could	unbalance	
system	homeostasis	and	result	in	unintended	consequences	such	as	
collateral	tissue	damage,	autoimmune	complications,	and	nonspecific	
side	effects.	Therefore,	it	is	important	to	notice	that	modern	technol-
ogies	could	also	result	in	costs	like	overdiagnosis	and	overtreatment.
Modern	humans	live	longer	than	our	ancestors	because	of	benign	
and	 infrequent	 exposure	 to	 infectious	 diseases,	 predation,	 and	 vio-
lence.	This	situation	results	in	increased	cancer	incidence	because	the	
largest	 risk	 factor	 for	most	cancers	 is	 simply	aging	 (Frank,	2007).	By	
considering	differences	between	what	natural	selection	acts	on	(repro-
ductive	fitness)	 and	our	 current	 goals	 in	 the	modern	world	 (improv-
ing	health	 and	well-	being),	 it	may	be	possible	 to	 identify	 aspects	 of	
anticancer	adaptations	that	have	been	constrained	by	trade-	offs	and	
so	may	be	effective	targets	for	intervention.	In	fact,	as	evolution	has	
not	apparently	strongly	selected	for	late-	life	cancer	prevention	(Frank,	
2007),	this	may	represent	an	opportunity	to	“do	better”	than	evolution’s	
current	 prescription.	 For	 instance,	 ontogeny	 requires	 that	 cells	 have	
the	capacity	to	move	and	proliferate,	capacities	which	may	be	“reac-
tivated”	in	cancer.	After	development	is	completed,	it	may	be	possible	
to	constrain	somatic	cell	phenotypes	so	that	they	are	less	likely	to	call	
upon	developmental	programs	reducing	risk	of	cancer	development.
To	 conclude,	we	 emphasize	 the	 benefits	 of	 playing	 by	 the	 evo-
lutionary	rules	that	regulate	the	risk	of	cancer,	 rather	than	adopting	
treatment	 of	 symptoms.	 This	 work	 calls	 for	 a	 more	 integrated	 ap-
proach	to	cancer	research	that	will	consider	evolutionary	trade-	offs.	
In	particular,	treatment	strategies	that	will	shift	these	trades-	offs	away	
from	cancer	and	favor	the	host	may	be	a	promising	way	to	discover	
new	methods	of	prevention	and	treatment.
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